Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.32 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.32 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470271 | 0.76 | ALDH1A1 (0.34) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL857633 | 0.76 | MAPT (0.34) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL29266188 | 0.74 | MAPT (0.33) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL5750909 | 0.72 | HTT (0.35) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL5748471 | 0.72 | GABRA1 (0.36) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL4461039 | 0.72 | NQO2 (0.41) | ALDH1A1KDM4EMAPTHPGDPOLB | |
| SCHEMBL5750689 | 0.72 | TRIM24 (0.39) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL6465602 | 0.70 | PARP1 (0.50) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL29404834 | 0.70 | PARP1 (0.50) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL5747005 | 0.69 | PARP1 (0.44) | ALDH1A1KDM4EMAPTHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521454-B2 | Adenine derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1386923-B1 | NOVEL ADENINE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7157465-B2 | Adenine derivatives | DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| CN-1250548-C | Novel adenine derivatives | SUMITOMO PHARMA (JP) | 2006-04-12 | — | — | CN | disclosed |
| CN-1512992-A | Novel adenine derivatives | ס����ҩ��ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| CN-1038930-C | Azetidinone derivatives useful in preparation of carbapenem antibiotics | SANKYO CO (JP) | 1998-07-01 | — | — | CN | disclosed |
| EP-0845459-A1 | Azetidinone derivatives useful in the preparation of carbapenem antibiotics | Sankyo Company Limited (JP) | 1998-06-03 | — | — | EP | disclosed |
| US-5760050-A | SCHIZOPHRENIA | WARNER-LAMBERT COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| US-5719275-A | REACTING SILYL ENOL ETHER WITH AZETIDINONE DERIVATIVE TO FORM INTERMEDIATE FOR PENICILLIN-TYPE ANTIBIOTIC | SANKYO COMPANY, LIMITED (JP) | 1998-02-17 | — | — | US | disclosed |
| US-5681951-A | REACTING PENICILLIN DERIVATIVE HAVING SULFINYL OR SULFONYL GROUP IN 2 POSITION WITH SUBSTITUTED MERCAPTAN IN PRESENCE OF SALT OF GROUP IIA OR IIIA ELEMENT | SANKYO COMPANY, LIMITED (JP) | 1997-10-28 | — | — | US | disclosed |
| US-5614624-A | THIO SUBSTITUTED, ANTIBIOTICS, CHEMICAL INTERMEDIATES | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| US-5541317-A | PENICILLIN DERIVATIVES, CYCLIZATION OF ESTERS OR THIOESTERS | SANKYO COMPANY, LIMITED (JP) | 1996-07-30 | — | — | US | disclosed |
| CN-1068108-A | Be used to prepare the aza cyclo-butanone derivatives of carbapenem antibiotics | SANKYO CO (JP) | 1993-01-20 | — | — | CN | disclosed |
| EP-0516486-A2 | Azetidinone derivatives useful in the preparation of carbapenem antibiotics | Sankyo Company Limited (JP) | 1992-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | ALDH1A1 1181/4885KDM4E 2790/4885MEN1 4502/4885 |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | IRF3, IFNAR1, IFNG | ALDH1A1 2467/4885KDM4E 2317/4885MEN1 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.